A CHALLENGES AND CLINICAL IMPLICATION IN DAPSONEINDUCED HYPERSENSITIVITY SYNDROME IN BORDERLINE TUBERCULOID HANSEN'S DISEASE

An essential sulfone medication, dapsone was created in 1908 and is mostly used to treat leprosy and otherdermatological disorders. 0.2% to 0.5% of users have dapsone hypersensitivity syndrome (DHS), which wasinitially identified in 1949. If left untreated, DHS can cause severe systemic symptoms that could result in organdamage or even death. DHS is characterised by a delayed onset that can happen anywhere from two hours tosix months after exposure. It involves processes such as the creation of inflammatory cytokines. Skinhypersensitivity responses and haemolytic anaemia associated to dosage are important adverse effects.A 42-year-old housewife with borderline tuberculoid leprosy showed up with extensive red lesions that turnedinto yellowish pustules over the course of four days, as well as hand and foot oedema, pain, and itching. Atrophic ulcer on her right sole, hyperpigmented patches, and non-blanchable erythema and pustules on herface, upper and lower limbs, chest, and belly were all found during the examination. She had steady vital signsand no systemic symptoms.